#stayhome Maintain the distance, wash your hands, and follow instructions from the health authorities.
RSS   Newsletter   Contact   Advertise with us

Endo International to buy Par Pharmaceutical for $8 billion

Share on Twitter Share on LinkedIn
Staff writer ▼ | May 18, 2015
Endo International Plc said it would buy Par Pharmaceutical Holdings from TPG Capital for about $8 billion, including debt.
Endo International
Acquisition   $6.5 billion in cash for Par Pharma
Endo's offer consists of about 18 million shares and $6.5 billion in cash, the company said.

Par Pharmaceutical was acquired by TPG Capital for $1.9 billion in 2012 following pressure from activist firm Relational Investors LLC to sell itself. The company, which filed with U.S. regulators in March for an initial public offering of common stock, had debt of $2.35 billion as of March 31.

Par operates through its generics division, Par Pharmaceutical, and its proprietary products division, Strativa Pharmaceuticals.

Endo said it had secured financing from Deutsche Bank and Barclays to fund the cash consideration.